TY - JOUR
T1 - Application of volumetric absorptive microsampling for robust, high-throughput mass spectrometric quantification of circulating protein biomarkers
AU - van den Broek, Irene
AU - Fu, Qin
AU - Kushon, Stuart
AU - Kowalski, Michael P.
AU - Millis, Kevin
AU - Percy, Andrew
AU - Holewinski, Ronald J.
AU - Venkatraman, Vidya
AU - Van Eyk, Jennifer E.
N1 - Publisher Copyright:
© 2017 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL)
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Volumetric absorptive micro sampling (VAMS™) allows accurate sampling of 10 µL of blood from a minimally invasive finger prick and could enable remote personalized health monitoring. Moreover, VAMS overcomes effects from hematocrit and sample heterogeneity associated with dried blood spots (DBS). We describe the first application of VAMS with the Mitra® microsampling device for the quantification of protein biomarkers using an automated, high-throughput sample preparation method coupled with mass spectrometric (MS) detection. The analytical performance of the developed workflow was evaluated for 10 peptides from six clinically relevant proteins: apolipoproteins A-I, B, C-I, C-III, E, and human serum albumin (HSA). Extraction recovery from blood with three different levels of hematocrit varied between 100% and 111% for all proteins. Within-day and total assay reproducibility (i.e., 5 replicates on 5 days) ranged between 3.2–10.4% and 3.4–12.6%, respectively. In addition, after 22 weeks of storage of the Mitra microsampling devices at −80 °C, all peptide responses were within ±15% deviation from the initial response. Application to data-independent acquisition (DIA) MS further demonstrated the potential for broad applicability and the general robustness of the automated workflow by reproducible detection of 1661 peptides from 423 proteins (average 15.7%CV (n = 3) in peptide abundance), correlating to peptide abundances in corresponding plasma (R = 0.8383). In conclusion, we have developed an automated workflow for efficient extraction, digestion, and MS analysis of a variety of proteins in a fixed small volume of dried blood (i.e., 10 µL). This robust and high-throughput workflow will create manifold opportunities for the application of remote, personalized disease biomarker monitoring.
AB - Volumetric absorptive micro sampling (VAMS™) allows accurate sampling of 10 µL of blood from a minimally invasive finger prick and could enable remote personalized health monitoring. Moreover, VAMS overcomes effects from hematocrit and sample heterogeneity associated with dried blood spots (DBS). We describe the first application of VAMS with the Mitra® microsampling device for the quantification of protein biomarkers using an automated, high-throughput sample preparation method coupled with mass spectrometric (MS) detection. The analytical performance of the developed workflow was evaluated for 10 peptides from six clinically relevant proteins: apolipoproteins A-I, B, C-I, C-III, E, and human serum albumin (HSA). Extraction recovery from blood with three different levels of hematocrit varied between 100% and 111% for all proteins. Within-day and total assay reproducibility (i.e., 5 replicates on 5 days) ranged between 3.2–10.4% and 3.4–12.6%, respectively. In addition, after 22 weeks of storage of the Mitra microsampling devices at −80 °C, all peptide responses were within ±15% deviation from the initial response. Application to data-independent acquisition (DIA) MS further demonstrated the potential for broad applicability and the general robustness of the automated workflow by reproducible detection of 1661 peptides from 423 proteins (average 15.7%CV (n = 3) in peptide abundance), correlating to peptide abundances in corresponding plasma (R = 0.8383). In conclusion, we have developed an automated workflow for efficient extraction, digestion, and MS analysis of a variety of proteins in a fixed small volume of dried blood (i.e., 10 µL). This robust and high-throughput workflow will create manifold opportunities for the application of remote, personalized disease biomarker monitoring.
KW - Apolipoproteins
KW - Data-independent acquisition
KW - Dried blood
KW - Mass spectrometry
KW - Remote monitoring
KW - Selected reaction monitoring
UR - http://www.scopus.com/inward/record.url?scp=85046553253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046553253&partnerID=8YFLogxK
U2 - 10.1016/j.clinms.2017.08.004
DO - 10.1016/j.clinms.2017.08.004
M3 - Article
AN - SCOPUS:85046553253
SN - 2376-9998
VL - 4-5
SP - 25
EP - 33
JO - Clinical Mass Spectrometry
JF - Clinical Mass Spectrometry
ER -